Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers
- PMID: 26669792
- PMCID: PMC5586150
- DOI: 10.1089/apc.2015.0240
Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers
Conflict of interest statement
TL, NO, YV, OA, and JE are employed by Amida Care which receives research funding from Gilead Sciences. JL, M. B-I, and SK are employed by ACRIA which receives research funding from Gilead Sciences. MK, KA, and DN report no conflicts.
References
-
- Matthews PC, Geretti AM, Goulder PJ, et al. . Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol 2014;61:20–33 - PubMed
-
- Puoti M, Moioli MC, Travi G, et al. . The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis 2012;32:103–113 - PubMed
-
- Smith C, Sabin CA, Lundgren JD, et al. . Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537–1548 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical